The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

R. Briski, Andrew L Feldman, N. G. Bailey, M. S. Lim, K. Ristow, Thomas Matthew Habermann, W. R. Macon, D. J. Inwards, J. P. Colgan, Grzegorz S Nowakowski, M. S. Kaminski, Thomas Elmer Witzig, Stephen Maxted Ansell, R. A. Wilcox

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline-and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

Original languageEnglish (US)
Article numbere214
JournalBlood Cancer Journal
Volume4
Issue number5
DOIs
StatePublished - 2014

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this